|
Jul 25
|
Coya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains?
|
|
Jul 24
|
Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson’s Disease
|
|
Jul 22
|
Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025
|
|
Jun 18
|
iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 24-25, 2025
|
|
Jun 18
|
Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025
|
|
Apr 17
|
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
|
|
Apr 11
|
Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?
|
|
Feb 25
|
Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer’s Disease Using GLP-1 Agonists and Combinations
|
|
Feb 4
|
Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
|
|
Sep 24
|
Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference
|
|
Aug 12
|
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results
|
|
Jul 31
|
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
|
|
Jun 11
|
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
|
|
May 20
|
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)
|
|
May 14
|
Coya Therapeutics, Inc.'s (NASDAQ:COYA) largest shareholders are retail investors with 60% ownership, insiders own 16%
|
|
Apr 18
|
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
|
|
Feb 21
|
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a "Pipeline in a Product"
|
|
Jan 16
|
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis
|
|
Jan 16
|
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
|
|
Jan 5
|
Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
|